Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619109 · ClinicalTrials.gov registry record
Determination of Normal Reference Values of CRP, Procalcitonin, and Lactate Levels for the Nanōmix eLab® System
A clinical trial, sponsored by Nanomix.
- Completed
- Registry status
- 160
- Enrollment target
NCT03619109: Completed study, sponsored by Nanomix.
NCT03619109 is a clinical trial that has completed, run by Nanomix. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03619109 has completed, sponsored by Nanomix.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
The main objective of this clinical study is to determine the normal reference range of the Nanōmix eLab® (eLab) C-Reactive Protein, Procalcitonin and Lactate Assay.
Primary Outcome
To determine the normal reference ranges of CRP, Procalcitonin, and Lactate for the Nanōmix eLab® System using Li-Heparinized venous whole blood and Li-Heparinized plasma samples from healthy subjects.System using Li-Heparinized venous whole blood and Li-Heparinized plasma samples from healthy subjects.Nanōmix eLab® System.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2019-02-28 |
What the finished NCT03619109 record still lists
NCT03619109 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03619109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03619109 about?
NCT03619109 is a clinical study titled "Determination of Normal Reference Values of CRP, Procalcitonin, and Lactate Levels for the Nanōmix eLab® System". The main objective of this clinical study is to determine the normal reference range of the Nanōmix eLab® (eLab) C-Reactive Protein, Procalcitonin and Lactate Assay.
What is the current status of trial NCT03619109?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2017-12-22. Estimated completion is 2019-02-28.
Who is sponsoring clinical trial NCT03619109?
This trial is sponsored by Nanomix, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI